动脉瘤性蛛网膜下腔出血患者脑室外引流管拔除或更换与预防性抗凝的关联:倾向校正分析
本研究回顾性分析2014年1月1日至2019年7月31日期间放置脑室外引流的动脉瘤性蛛网膜下腔出血患者,比较拔管前停用预防性抗凝>1剂与≤1剂两组,主要结局为拔管后深静脉血栓或肺栓塞。共271例,停用>1剂116例(42.8%)。校正后停用>1剂与深静脉血栓或肺栓塞发生相关(OR 4.8;95%CI 1.5-15.7;p=0.009),且未降低拔管相关出血。
要点
- 拔管前停用>1剂预防性抗凝与深静脉血栓或肺栓塞风险升高相关(OR 4.8)。
- 停用>1剂与≤1剂相比,拔管相关出血无显著差异(3.5% vs 1.3%;p=0.41)。
- 未停用与停用≥1剂相比,拔管相关出血无显著差异(1.0% vs 2.9%;p=0.32)。
核心结论
- 在放置脑室外引流的动脉瘤性蛛网膜下腔出血患者中,拔管前停用>1剂预防性抗凝与深静脉血栓或肺栓塞风险增加相关,且未减少拔管相关出血。
研究设计与样本
- 回顾性分析2014年1月1日至2019年7月31日期间接受脑室外引流的动脉瘤性蛛网膜下腔出血患者,共271例。
- 根据拔管前停用预防性抗凝剂次数分为>1剂与≤1剂两组,并进行倾向校正的逻辑回归分析。
主要发现
- 拔管前停用>1剂预防性抗凝者116例(42.8%)。
- 6例(2.2%)发生拔管相关出血,17例(6.3%)发生深静脉血栓或肺栓塞。
- 停用>1剂与≤1剂相比,拔管相关出血无显著差异(4/116[3.5%] vs 2/155[1.3%];p=0.41)。
- 未停用与停用≥1剂相比,拔管相关出血无显著差异(1/100[1.0%] vs 5/171[2.9%];p=0.32)。
- 校正后,停用>1剂与≤1剂相比,深静脉血栓或肺栓塞发生风险升高(OR 4.8;95%CI 1.5-15.7;p=0.009)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Withholding prophylactic anticoagulation from patients with aneurysmal subarachnoid hemorrhage (aSAH) before external ventricular drain (EVD) removal or replacement remains controversial. This study analyzed whether prophylactic anticoagulation was associated with hemorrhagic complications related to EVD removal. METHOD: All aSAH patients treated from January 1, 2014, to July 31, 2019, with an EVD placed were retrospectively analyzed. Patients were compared based on the number of prophylactic anticoagulant doses withheld for EVD removal (> 1 vs. ≤ 1). The primary outcome analyzed was deep venous thrombosis (DVT) or pulmonary embolism (PE) after EVD removal. A propensity-adjusted logistic-regression analysis was performed for confounding variables. RESULTS: A total of 271 patients were analyzed. For EVD removal, > 1 dose was withheld from 116 (42.8%) patients. Six (2.2%) patients had a hemorrhage associated with EVD removal, and 17 (6.3%) patients had a DVT or PE. No significant difference in EVD-related hemorrhage after EVD removal was found between patients with > 1 versus ≤ 1 dose of anticoagulant withheld (4 of 116 [3.5%] vs. 2 of 155 [1.3%]; p = 0.41) or between those with no doses withheld compared to ≥ 1 dose withheld (1 of 100 [1.0%] vs. 5 of 171 [2.9%]; p = 0.32). After adjustment, withholding > 1 dose of anticoagulant versus ≤ 1 dose was associated with the occurrence of DVT or PE (OR 4.8; 95% CI, 1.5-15.7; p = 0.009). CONCLUSIONS: In aSAH patients with EVDs, withholding > 1 dose of prophylactic anticoagulant for EVD removal was associated with an increased risk of DVT or PE and no reduction in catheter removal-associated hemorrhage.
引用
- Catapano JS, Koester SW, Parikh PP, et al. Association between external ventricular drain removal or replacement and prophylactic anticoagulation in patients with aneurysmal subarachnoid hemorrhage: a propensity-adjusted analysis. Acta Neurochir (Wien). 2023. PMID: 37301800. doi:10.1007/s00701-023-05651-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。